APP transgenic mice: The effect of active and passive immunotherapy in cognitive tasks

Neuroscience and Biobehavioral Reviews

Volumn 34, Issue 4, 2010, Pages 487-499

  Röskam, Stephan ^a   Neff, Frauke ^a   Schwarting, Rainer ^a   Bacher, Michael ^a   Dodel, Richard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Amyloid; Alzheimer's disease; Amyloid precursor protein; Animal model; Behavior; Cognition; Immunization; Transgenic mice

Indexed keywords

ACI 01; ACI 24; ADENOVIRUS VECTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN ANTIBODY 10D5; AMYLOID BETA PROTEIN[1-15]; AMYLOID BETA PROTEIN[1-16]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[1-4]; AMYLOID BETA PROTEIN[28-30] ANTIBODY; AMYLOID BETA PROTEIN[33-40] ANTIBODY; AMYLOID PRECURSOR PROTEIN; EPITOPE; ESCHERICHIA COLI ENTEROTOXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPES SIMPLEX VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 4; K6 AMYLOID BETA PROTEIN[1-30]; LIPOSOME; M 266; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 20.1; MONOCLONAL ANTIBODY BAM 10; NAB 61; PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; COGNITION; CONTROLLED STUDY; EMOTION; LEARNING; MEMORY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; COGNITION DISORDERS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; MICE; MICE, TRANSGENIC; NEUROPSYCHOLOGICAL TESTS; RECEPTORS, CELL SURFACE;

EID: 77649189880     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2009.10.006     Document Type: Review

References (88)

1. Aggleton J.P. One-trial object recognition by rats. Q. J. Exp. Psychol. 1985, 37:279-294.
2. Aggleton J.P., Brown M.W. Episodic memory, amnesia, and the hippocampal-anterior thalamic axis. Behav. Brain Sci. 1999, 22:425-444. discussion 444-489.
3. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatrie Psychisch-gerichtliche Medizin 1907, 64:146-148.
4. Arendash G.W., King D.L., Gordon M.N., Morgan D., Hatcher J.M., Hope C.E., Diamond D.M. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 2001, 891:42-53.
5. Arendash G.W., Gordon M.N., Diamond D.M., Austin L.A., Hatcher J.M., Jantzen P., DiCarlo G., Wilcock D., Morgan D. Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol. 2001, 20:737-744.
6. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 2009, 118:167-179.
7. Asuni A.A., Boutajangout A., Scholtzova H., Knudsen E., Li Y.S., Quartermain D., Frangione B., Wisniewski T., Sigurdsson E.M. Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur. J. Neurosci. 2006, 24:2530-2542.
8. Austin L., Arendash G.W., Gordon M.N., Diamond D.M., DiCarlo G., Dickey C., Ugen K., Morgan D. Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP+PS1 mice. Behav. Neurosci. 2003, 117:478-484.
9. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
10. Barnes C.A. Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J. Comp. Physiol. Psychol. 1979, 93:74-104.
11. Baxevanis C.N., Perez S.A., Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol. Immunother. 2009, 58:317-324.
12. Bertaina-Anglade V., Enjuanes E., Morillon D., Drieu L.R. The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity. J. Pharmacol. Toxicol. Methods 2006, 54(2):99-105.
13. Bevins R.A., Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'. Nat. Protoc. 2006, 1:1306-1311.
14. Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005, 45:675-688.
15. Brody D.L., Holtzman D.M. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci. 2008.
16. Chen G., Chen K.S., Kobayashi D., Barbour R., Motter R., Games D., Martin S.J., Morris R.G. Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J. Neurosci. 2007, 27:2654-2662.
17. Cheng I.H., Palop J.J., Esposito L.A., Bien-Ly N., Yan F., Mucke L. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat. Med. 2004, 10:1190-1192.
18. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001, 276:21562-21570.
19. Crawley J.N. What's Wrong With My Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice 2000, Wiley-Liss.
20. Cummings J.L., Doody R., Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007, 69:1622-1634.
21. Deacon R.M. Appetitive position discrimination in the T-maze. Nat. Protoc. 2006, 1:13-15.
22. Delavallee L., Assier E., Denys A., Falgarone G., Zagury J.F., Muller S., Bessis N., Boissier M.C. Vaccination with cytokines in autoimmune diseases. Ann. Med. 2008, 40:343-351.
23. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8850-8855.
24. Dere E., Huston J.P., Souza Silva M.A. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci. Biobehav. Rev. 2007, 31:673-704.
25. Dickson D.W. Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol. Aging 1997, 18:S21-S26.
26. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 2002, 5:452-457.
27. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav. Brain Res. 1988, 31:47-59.
28. Eriksen J.L., Janus C.G. Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav. Genet. 2007, 37:79-100.
29. Fendt M., Fanselow M.S. The neuroanatomical and neurochemical basis of conditioned fear. Neurosci. Biobehav. Rev. 1999, 23:743-760.
30. Frazer M.E., Hughes J.E., Mastrangelo M.A., Tibbens J.L., Federoff H.J., Bowers W.J. Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4. Mol. Ther. 2008, 16:845-853.
31. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
32. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
33. Götz J., Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 2008, 9:532-544.
34. Gulinello M., Chen F., Dobrenis K. Early deficits in motor coordination and cognitive dysfunction in a mouse model of the neurodegenerative lysosomal storage disorder, Sandhoff disease. Behav. Brain Res. 2008, 193(2):315-319.
35. Guo Q., Sebastian L., Sopher B.L., Miller M.W., Ware C.B., Martin G.M., Mattson M.P. Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: central roles of superoxide production and caspase activation. J. Neurochem. 1999, 72:1019-1029.
36. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
37. Hara H., Monsonego A., Yuasa K., Adachi K., Xiao X., Takeda S., Takahashi K., Weiner H.L., Tabira T. Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J. Alzheimers Dis. 2004, 6:483-488.
38. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 1991, 12:383-388.
39. Hartman R.E., Izumi Y., Bales K.R., Paul S.M., Wozniak D.F., Holtzman D.M. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J. Neurosci. 2005, 25:6213-6220.
40. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
41. Hughes R.N. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci. Biobehav. Rev. 2004, 28:497-505.
42. Ihara Y., Nukina N., Miura R., Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J. Biochem. 1986, 99:1807-1810.
43. Janus C. Search strategies used by APP transgenic mice during navigation in the Morris water maze. Learn. Mem. 2004, 11:337-346.
44. Janus C., Chishti M.A., Westaway D. Transgenic mouse models of Alzheimer's disease. Biochim. Biophys. Acta 2000, 1502:63-75.
45. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
46. Jensen M.T., Mottin M.D., Cracchiolo J.R., Leighty R.E., Arendash G.W. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience 2005, 130:667-684.
47. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
48. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Younkin S., Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 2002, 22:6331-6335.
49. Kumar-Singh S., Dewachter I., Moechars D., Lubke U., De Jonghe C., Ceuterick C., Checler F., Naidu A., Cordell B., Cras P., Van Broeckhoven C., van Leuven F. Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. Neurobiol. Dis. 2000, 7:9-22.
50. Lavie V., Becker M., Cohen-Kupiec R., Yacoby I., Koppel R., Wedenig M., Hutter-Paier B., Solomon B. EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J. Mol. Neurosci. 2004, 24:105-113.
51. LeDoux J.E., Lane R.D., Nadel L. Cognitive-emotional interactions: listen to the Brain. Cognitive Neuroscience of Emotion 2000, 129-155. Oxford University Press, New York, Oxford. R.J. Davidson, P. Ekman, K. Scherer (Eds.).
52. Lee E.B., Leng L.Z., Zhang B., Kwong L., Trojanowski J.Q., Abel T., Lee V.M. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J. Biol. Chem. 2006, 281:4292-4299.
53. Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Desai R., Hancock W.W., Weiner H.L., Selkoe D.J. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. N. Y. Acad. Sci. 2000, 920:328-331.
54. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 1999, 155:853-862.
55. Maier M., Seabrook T.J., Lazo N.D., Jiang L., Das P., Janus C., Lemere C.A. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci. 2006, 26:4717-4728.
56. Mandelkow E., von Bergen M., Biernat J., Mandelkow E.M. Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol. 2007, 17:83-90.
57. Maren S. Neurobiology of Pavlovian fear conditioning. Annu. Rev. Neurosci. 2001, 24:897-931.
58. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 1999, 46:860-866.
59. Moechars D., Dewachter I., Lorent K., Reverse D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Haute C.V., Checler F., Godaux E., Cordell B., van Leuven F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 1999, 274:6483-6492.
60. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
61. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 1984, 11:47-60.
62. Mouri A., Noda Y., Hara H., Mizoguchi H., Tabira T., Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J. 2007, 21:2135-2148.
63. Movsesyan N., Ghochikyan A., Mkrtichyan M., Petrushina I., Davtyan H., Olkhanud P.B., Head E., Biragyn A., Cribbs D.H., Agadjanyan M.G. Reducing AD-like pathology in 3×Tg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS ONE 2008, 3:e2124.
64. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20:4050-4058.
65. Muhs A., Hickman D.T., Pihlgren M., Chuard N., Giriens V., Meerschman C., van d.A.I., van Leuven F., Sugawara M., Weingertner M.C., Bechinger B., Greferath R., Kolonko N., Nagel-Steger L., Riesner D., Brady R.O., Pfeifer A., Nicolau C. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:9810-9815.
66. Neff F., Wei X., Nolker C., Bacher M., Du Y., Dodel R. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun. Rev. 2008, 7:501-507.
67. Neve R.L., McPhie D.L., Chen Y. Alzheimer's disease: a dysfunction of the amyloid precursor protein(1). Brain Res. 2000, 886:54-66.
68. Newman M., Musgrave I.F., Lardelli M. Alzheimer disease: amyloidogenesis, the presenilins and animal models. Biochim. Biophys. Acta 2007, 1772:285-297.
69. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
70. Oddo S., Vasilevko V., Caccamo A., Kitazawa M., Cribbs D.H., LaFerla F.M. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 2006, 281:39413-39423.
71. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
72. Pitschke M., Prior R., Haupt M., Riesner D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat. Med. 1998, 4:832-834.
73. Radde R., Bolmont T., Kaeser S.A., Coomaraswamy J., Lindau D., Stoltze L., Calhoun M.E., Jaggi F., Wolburg H., Gengler S., Haass C., Ghetti B., Czech C., Holscher C., Mathews P.M., Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006, 7:940-946.
74. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
75. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
76. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008, 192(1):106-113.
77. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14(8):837-842.
78. Sigurdsson E.M., Scholtzova H., Mehta P.D., Frangione B., Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 2001, 159:439-447.
79. Sigurdsson E.M., Knudsen E., Asuni A., Fitzer-Attas C., Sage D., Quartermain D., Goni F., Frangione B., Wisniewski T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J. Neurosci. 2004, 24:6277-6282.
80. Solomon B. Active immunization against Alzheimer's beta-amyloid peptide using phage display technology. Vaccine 2007, 25:3053-3056.
81. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:13287-13292.
82. Van Dam D., De Deyn P.P. Drug discovery in dementia: the role of rodent models. Nat. Rev. Drug Discov. 2006, 5:956-970.
83. Van Dam D., Lenders G., De Deyn P.P. Effect of Morris water maze diameter on visual-spatial learning in different mouse strains. Neurobiol. Learn. Mem. 2006, 85:164-172.
84. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
85. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 2004, 1:24.
86. Wilcock D.M., Alamed J., Gottschall P.E., Grimm J., Rosenthal A., Pons J., Ronan V., Symmonds K., Gordon M.N., Morgan D. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci. 2006, 26:5340-5346.
87. Zhang J., Wu X., Qin C., Qi J., Ma S., Zhang H., Kong Q., Chen D., Ba D., He W. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2003, 14:365-379.
88. Zou J., Yao Z., Zhang G., Wang H., Xu J., Yew D.T., Forster E.L. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response. J. Neurol. Sci. 2008, 272:87-98.